Mid and long-term results of the Supera® stent in femoropopliteal obstructive disease: a comprehensive analysis of the literature
DOI:
https://doi.org/10.48750/acv.556Keywords:
Endovascular, implantomimetic stent, peripheral artery disease, femoropolitealAbstract
INTRODUCTION
The femoropopliteal biomechanical characteristics make the endovascular treatment of complex lesions particularly challenging. Despite several studies reporting longer patency of femoropopliteal stenting when compared to balloon angioplasty, long-term outcomes are still marginal due to the high rate of restenosis, stent fracture, and thrombosis. This study aims to review the current literature on the outcomes of the endovascular treatment of the femoropopliteal sector with the Supera® stent. MATERIALS AND METHODS
A search was carried on Pubmed database under the terms [“Supera” AND “femoropopliteal”]. Prospective and retrospective original studies were selected after title and abstract analysis.
RESULTS
Twelve studies were analyzed, comprising a total of 1358 limbs with femoropopliteal obstructive disease treated with the Supera® stent. The 12-month primary-patency rate (PPR) ranged from 72.6% to 94.1%, the 24-month PPR ranged from 60.8% to 83.1% and the 36-month PPR ranged from 69.5% to 76.7%. For high-complexity anatomies, including TASC C and D lesions, the 12-month PPR was >64%. There were no stent fractures reported in any of the included studies.
DISCUSSION
The Supera® stent showed promising results for the endovascular treatment of the femoropopliteal sector, highlighting its performance in high-complexity anatomic patterns.
Downloads
References
San Norberto EM, Flota CM, Fidalgo-Domingos L, Taylor JH, Vaquero C. Real-World Results of Supera Stent Implantation for Popliteal Artery Atherosclerotic Lesions: 3-Year Outcome. Ann Vasc Surg. 2020;62:397-405.
Scheinert D, Scheinert S, Sax J, Piorkowski C, Bräunlich S, Ulrich M, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312-5.
Guzzardi G, Spinazzola A, Cangiano G, Natrella M, Paladini A, Porta C, et al. Endovascular treatment of femoro-popliteal disease with the Supera stent: results of a multicenter study. J Public Health Res. 2021;11: 2360
Bishu K, Armstrong EJ. Supera self-expanding stents for endovascular treatment of femoropopliteal disease: a review of the clinical evidence. Vasc Health Risk Manag 2015;11:387-95.
Low J, Shih T, Lu E, Derubertis BG, Baril DT. Midterm Results of the Supera Stent for the Treatment of Femoropopliteal Occlusive Disease. Ann Vasc Surg. 2022; 86:177-183
León LR Jr., Dieter RS, Gadd CL, Ranellone E, Mills JL Sr., Montero-Baker MF, et al. Preliminary results of the initial United States experience with the Supera woven nitinol stent in the popliteal artery. J Vasc Surg. 2013;57:1014-22.
George JC, Rosen ES, Nachtigall J, VanHise A, Kovach R. SUPERA interwoven nitinol Stent Outcomes in Above-Knee IntErventions (SAKE) study. J Vasc Interv Radiol 2014;25:954-61
Maleckis K, Deegan P, Poulson W, Sievers C, Desyatova A, MacTaggart J, et al. Comparison of femoropopliteal artery stents under axial and radial compression, axial tension, bending, and torsion deformations. Journal of the mechanical behavior of biomedical materials. J Mech Behav Biomed Mater. 2017;75:160-8
MacTaggart J, Poulson W, Seas A, Deegan P, Lomneth C, Desyatova A, et al. Stent Design Affects Femoropopliteal Artery Deformation. Ann Surg. 2019;270:180-7.
San Norberto EM, Fidalgo-Domingos LA, García-Saiz I, Taylor J, Vaquero C. Endovascular Treatment of Popliteal Artery Occlusion Caused by a Ruptured Supera Interwoven Nitinol Stent. Ann Vas Surg. 2019;59:308.e9-.e13
Van Meirvenne E, Reyntjens P, Tielemans Y. Self-expanding interwoven nitinol stent in severe femoropopliteal arterial disease. Real life results of the Supera Peripheral Stent System(®). Acta Chir Belg. 2023:462-72.
Myint M, Schouten O, Bourke V, Thomas SD, Lennox AF, Varcoe RL. A Real-World Experience With the Supera Interwoven Nitinol Stent in Femoropopliteal Arteries: Midterm Patency Results and Failure Analysis. J Endovasc Ther. 2016;23:433-41.
Nasr B, Gouailler F, Marret O, Guillou M, Chaillou P, Guyomarc'h B, et al. Treatment of Long Femoropopliteal Lesions With Self-Expanding Interwoven Nitinol Stent: 24 Month Outcomes of the STELLA-SUPERA Trial. J Endovasc Ther. 2023;30:98-105
Brescia AA, Wickers BM, Correa JC, Smeds MR, Jacobs DL. Stenting of femoropopliteal lesions using interwoven nitinol stents. J Vasc Surg. 2015;61:1472-8.
Montero-Baker M, Ziomek GJ, Leon L, Gonzales A, Dieter RS, Gadd CL, et al. Analysis of endovascular therapy for femoropopliteal disease with the Supera stent. J Vasc Surg. 2016;64:1002-8.
Low J, Shih T, Lu E, Derubertis BG, Baril DT. Midterm Results of the Supera Stent for the Treatment of Femoropopliteal Occlusive Disease. Ann Vasc Surg. 2022;86:177-83.
Garcia L, Jaff MR, Metzger C, Sedillo G, Pershad A, Zidar F, et al. Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the SUPERB Trial. Circ Cardiovasc Interv. 2015;8: e000937.
Palena LM, Diaz-Sandoval LJ, Sultato E, Brigato C, Candeo A, Brocco E, et al. Feasibility and 1-Year outcomes of subintimal revascularization with supera(®) stenting of long femoropopliteal occlusions in critical limb ischemia: The "Supersub" Study. Catheter Cardiovasc Interv. 2017;89:910-20
Gostev AA, Osipova OS, Saaya SB, Bugurov SV, Cheban AV, Rabtsun AA, et al. Bypass Versus Interwoven Nitinol Stents for Long Femoro-Popliteal Occlusions: A Propensity Matched Analysis. Cardiovasc Interv Radiol. 2022;45:929-38.
Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Eur J Vasc Endovasc Surg. 2019;58:S1-S109.
Zeller T. Current state of endovascular treatment of femoro-popliteal artery disease. Vasc Med. 2007;12:223-34.
Gray WA, Feiring A, Cioppi M, Hibbard R, Gray B, Khatib Y, et al. S.M.A.R.T. self-expanding nitinol stent for the treatment of atherosclerotic lesions in the superficial femoral artery (STROLL): 1-year outcomes. J Vasc Interv Radiol. 2015;26:21-8.
Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329-40.
Sabeti S, Mlekusch W, Amighi J, Minar E, Schillinger M. Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries. J Endovasc Ther. 2005;12:6-12.
Dake MD, Scheinert D, Tepe G, Tessarek J, Fanelli F, Bosiers M, et al. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther. 2011;18:613-23.
Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701-10.
Rocha-Singh KJ, Bosiers M, Schultz G, Jaff MR, Mehta M, Matsumura JS. A single stent strategy in patients with lifestyle limiting claudication: 3-year results from the Durability II trial. Cathet Cardiovasc Interv. 2015;86:164-70.
Bosiers M, Deloose K, Callaert J, Moreels N, Keirse K, Verbist J, et al. Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg. 2011;54:1042-50.
Bosiers M, Torsello G, Gissler HM, Ruef J, Müller-Hülsbeck S, Jahnke T, et al. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther. 2009;16:261-9.
Davaine JM, Azéma L, Guyomarch B, Chaillou P, Costargent A, Patra P, et al. One-year clinical outcome after primary stenting for Trans-Atlantic Inter-Society Consensus (TASC) C and D femoropopliteal lesions (the STELLA "STEnting Long de L'Artère fémorale superficielle" cohort). Eur J Vasc Endovasc Surg. 2012;44:432-41.
Grenville JL, Tan KT, Moshonov H, Rajan DK. Endovascular first strategy for de novo TransAtlantic Inter-Society Consensus C and D femoro-popliteal disease: mid-term outcomes from a single tertiary referral center. Vascular. 2015;23:31-40.
Lin Y, Tang X, Fu W, Kovach R, George JC, Guo D. Stent Fractures After Superficial Femoral Artery Stenting: Risk Factors and Impact on Patency. J Endovasc Ther. 2015;22:319-26.
Bausback Y, Wittig T, Schmidt A, Zeller T, Bosiers M, Peeters P, et al. Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease. J Am Coll Cardiol. 2019;73:667-79.
Yang M, Shi B, Ma L, Yu C, Zhang X, Li T, et al. Treatment of Atherosclerotic Femoropopliteal Artery Disease with Supera Interwoven Nitinol Stent: A Real-World Study in China. Ann Vasc Surg. 2022;85:183-9.
Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V, et al. Drug-Eluting and Bare Nitinol Stents for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery: Long-Term Results from the SIROCCO Trial. J Endovasc Ther. 2006;13:701-10.
